Search Results - "Verhelst, X"

Association of recently described adipokines with liver histology in biopsy‐proven non‐alcoholic fatty liver disease: a systematic review by Bekaert, M, Verhelst, X, Geerts, A, Lapauw, B, Calders, P

“…The prevalence of non‐alcoholic fatty liver disease (NAFLD) is rising, as is the prevalence of obesity and type 2 diabetes. It is increasingly recognized that…”
Get full text

Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease by Lefere, S, Van de Velde, F, Devisscher, L, Bekaert, M, Raevens, S, Verhelst, X, Van Nieuwenhove, Y, Praet, M, Hoorens, A, Van Steenkiste, C, Van Vlierberghe, H, Lapauw, B, Geerts, A

“…Background: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and is strongly associated with obesity, dyslipidemia…”
Get full text

Recurrent rejections after liver transplantation for hepatocellular carcinoma with stem cell features in an adult patient by Meganck, S, Raevens, S, Ferdinande, K, Verhelst, X, Hoorens, A, Degroote, H, Geerts, A, Van Vlierberghe, H

“…Patients with hepatoblastoma featuring carcinoma characteristics have better outcomes after liver transplantation, than after chemotherapy and resection…”
Get full text

Diagnostic and prognostic scoring systems for autoimmune hepatitis: a review by Ducazu, O, Degroote, H, Geerts, A, Hoorens, A, Schouten, J, Van Vlierberghe, H, Verhelst, X

“…Auto-immune hepatitis (AIH) is a rare condition which primarily affects young women. Several diagnostic scoring systems exist based on clinical, biochemical,…”
Get more information

The potential of glycomics as prognostic biomarkers in liver disease and liver transplantation by Verhelst, X, Geerts, A, Callewaert, N, Van Vlierberghe, H

“…The study of glycomics is a novel and fascinating approach for the development of biomarkers. It has become clear that in the field of liver disease specific…”
Get more information

Pretransplant glycomic analysis of perfusate is predictive of primary non function after liver transplantation by Verhelst, X, Geerts, A, Vanderschaeghe, D, Rogiers, X, Vanlander, A, Berrevoet, F, Callewaert, N, Troisi, R.I, Van Vlierberghe, H

Get full text

A glycomic serum marker analysed at one week after liver transplantation is an independent predictor of graft loss during the first year after liver transplantation by Verhelst, X, Geerts, A, Rogiers, X, Vanlander, A, Berrevoet, F, Callewaert, N, Troisi, R.I, Van Vlierberghe, H

Get full text

Hepatitis E virus seroprevalence in East- and West Flanders, Belgium: Comparison between 2011 and 2016 by Cattoir, L, Nys, E, Van Vlierberghe, H, Geerts, A, Verhelst, X, Padalko, E

Get full text

Comorbidities and concomitant medications in patients with chronic hepatitis C virus infection receiving second-generation direct-acting antiviral regimens in Belgium: an observational study by Bourgeois, S, Mulkay, J P, Cool, M, Verhelst, X, Robaeys, G, Lasser, L, Lefebvre, V, Colle, I, Van Steenkiste, C, Decaestecker, J, Coulon, S, Venken, K, Vanwolleghem, T

“…To describe comorbidities and concomitant medications in patients initiating treatment for hepatitis C virus (HCV) infection with direct-acting antiviral (DAA)…”
Get more information

Hepatitis C virus (HCV) prevalence estimation in the adult general population in Belgium : a meta-analysis by Muyldermans, G, Bielen, R, Botterman, R, Bourgeois, S, Colle, I, Deressa, B, Devolder, G, Horsmans, Y, Hutse, V, Lanthier, N, Lasser, L, Platteau, S, Robaeys, G, Suin, V, Verhelst, X, Van Vlierberghe, H, Van Baelen, L

“…Although multiple HCV prevalence studies were recently performed in the general population from Belgium, they suffer from a lack of geographical…”
Get more information

Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis by De Rycke, L, Verhelst, X, Kruithof, E, Van den Bosch, F, Hoffman, I E A, Veys, E M, De Keyser, F

“…Objectives: To analyse the effect of infliximab on IgM rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodies, and determine whether…”
Get full text

Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in obese patients with non-alcoholic fatty liver disease by Lefere, S, Van de Velde, F, Devisscher, L, Bekaert, M, Raevens, S, Verhelst, X, Van Nieuwenhove, Y, Praet, M, Hoorens, A, Van Steenkiste, C, Van Vlierberghe, H, Lapauw, B, Geerts, A

Get full text

Kupffer cell pool is maintained by local proliferation and the differentiation of bone marrow monocytes into short-lived monocyte-derived Kupffer cells during non-alcoholic steatohepatitis and recovery by Devisscher, L, Scott, C.L, Lefere, S, Raevens, S, Bogaerts, E, Paridaens, A, Verhelst, X, Geerts, A, Guilliams, M, Van Vlierberghe, H

Get full text

Anti-placental growth factor therapy attenuates experimental hepatopulmonary syndrome by Raevens, S, Paridaens, A, Lefere, S, Casteleyn, C, Jonckx, B, Verhelst, X, Van Vlierberghe, H, Van Steenkiste, C, Geerts, A, Devisscher, L, Colle, I

Get full text

Comments on the impact of genotyping method on the subtype distribution of HCV genotype 1 by Borre, C.Van den, Schuermans, W, Van Vlierberghe, H, Geerts, A, Verhelst, X, Padalko, E

Get full text

Impact of the genotyping method on the distribution of hepatitis C virus subtypes of genotype 1 by Van den Borre, C, Schuermans, W, Van Vlierberghe, H, Geerts, A, Verhelst, X, Padalko, E

Get full text

P0075 : Health-related quality of life is improved after liver transplantation and is related to disease acceptance, helplessness and perceived disease benefits by Develtere, W, Onghena, L, Rogiers, X, Troisi, R.I, Berrevoet, F, Vanlander, A, Geerts, A, Van Vlierberghe, H, Verhelst, X, Poppe, C

Get full text

P0175 : Assessment of serum glycomics (glycocirrhotest) for risk prediction of hepatocellular carcinoma development in patients with cirrhosis by Verhelst, X, Vanderschaeghe, D, Castera, L, Geerts, A, Goutté, N, Francoz, C, Durand, F, Callewaert, N, Van Vlierberghe, H

Get full text

P1343 : Phase I dose-escalation study evaluating the safety and pharmacokinetics of oral artesunate in patients with advanced hepatocellular carcinoma (desparth trial) by Vandewynckel, Y.-P, Rombauts, K, Verhelst, X, Van Bortel, L, De Spiegeleer, B, Geerts, A, Van Vlierberghe, H

Get full text

Screening for hepatitis C viral infection in a non-urban primary care facility in Flanders by Verhelst, X, Devolder, G, De Wilde, M, Goderis, L, De Bel, A, Spillebeen, E, Geerts, A, Derese, A, Van Vlierberghe, H

Get more information